DRUG WATCH |
|
Year : 2014 | Volume
: 46
| Issue : 3 | Page : 334-336 |
Sorafenib-induced hand-foot syndrome in a patient of renal cell carcinoma
Amrita Sil1, Nilay Kanti Das2
1 Department of Pharmacology, Institute of Post Graduate Medical Education and Research, Kolkata, West Bengal, India 2 Department of Dermatology, Medical College, Kolkata, West Bengal, India
Correspondence Address:
Amrita Sil Department of Pharmacology, Institute of Post Graduate Medical Education and Research, Kolkata, West Bengal India
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/0253-7613.132189
Sorafenib, a multikinase inhibitor, is approved for treatment of renal cell cancer and hepatocellular cancer. Hand-foot syndrome (HFD) is a condition where erythema, scaling, and bullous lesion affect the hand and feet. In this case, a post-nephrectomy renal carcinoma patient prescribed sorafenib developed HFD 1 week after the drug usage. All laboratory parameters were within normal limits. The dose of sorafenib was reduced and topical corticosteroids, antihistamines, and emollients were prescribed. The reaction reduced after 2 weeks of therapy, only to reappear again when the second cycle of sorafenib-targeted therapy was started. The case was diagnosed as sorafenib-induced HFD.
[FULL TEXT] [PDF]*
|